Orlistat

• Description :

  Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1]. Anti-atherosclerotic effect[2].

• Product Name Alternative :

  Tetrahydrolipstatin; Ro-18-0647

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H412

• Target :

  Apoptosis; Fatty Acid Synthase (FASN)

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Metabolic Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/orlistat.html

• Concentration :

  10mM

• Purity :

  99.95

• Solubility :

  DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

• Smiles :

  O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](N([H])C([H])=O)CC(C)C)=O)CCCCCCCCCCC)O1

• Molecular Formula :

  C29H53NO5

• Molecular Weight :

  495.73

• Precautions :

  H302, H412

• References & Citations :

  [1]Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47 (2) :764-72.|[2]Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel) . 2021 Feb 6;10 (2) :251.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [96829-58-2]